Buserelin
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Buserelin: From Prostate Cancer to hypertrichosis
One-Sentence Summary
Buserelin is a GnRH (gonadotropin-releasing hormone) agonist peptide, used to treat prostate cancer. The TxGNN model predicts it may be effective for hypertrichosis, but only 0 clinical trials and 1 publication (a Cantu syndrome case report that does not describe buserelin treatment) are available, so the prediction rests almost entirely on the model.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prostate cancer (from pharmacology data; the approved indication text in the India licences is blank) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data |
| Number of Listed Products | 6 (valid: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled records. Based on known pharmacology, buserelin is a GnRH agonist that acts on the GnRH receptor (GNRHR). With continued use it suppresses the pituitary-gonadal axis and lowers sex steroid levels, which is the basis of its use in prostate cancer.
By lowering sex steroids and, indirectly, androgens, buserelin could plausibly reduce androgen-driven excess hair growth (hirsutism). However, generalized or congenital hypertrichosis is not androgen-dependent, so the mechanistic link is weak.
The only publication retrieved concerns Cantu syndrome, a condition that features hypertrichosis and hypopituitarism. It discusses endocrine monitoring and does not report buserelin treatment. The very high TxGNN score is a model prediction, not clinical evidence.
Other predicted indications (Ambras type hypertrichosis universalis congenita, malformation syndromes with dental or periodontal involvement, Dandy-Walker malformation syndromes, and isolated genetic hair shaft abnormalities) have no trials or literature and no plausible GnRH-related mechanism. Their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31743099 | 2019 | Review | Endocrinology, Diabetes & Metabolism Case Reports | Cantu syndrome (hypertrichosis with cardiac and skeletal anomalies) case with multiple pituitary hormone deficiencies; supports endocrine monitoring. No buserelin treatment reported. |
Currently no clinical trials are registered for this prediction.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 27449 | Busarlin 0.5mg Injection | Vial of 1 ml injection | Not stated |
| 207368 | Supradopin 0.5mg Injection | Vial of 1 ml injection | Not stated |
| 31391 | Busag 5mg Injection | Vial of 1 injection | Not stated |
| 28043 | Busarlin 7mg Injection | Vial of 7 ml injection | Not stated |
| 31264 | Busag 0.5mg Injection | Vial of 1 injection | Not stated |
A sixth licence (94767, Gynarich Injection, vial of 2.5 ml) is also valid. All six are single-ingredient injectables from Intas Pharmaceuticals, Serum Institute of India, and Zydus Cadila.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no supporting trials, and the single publication does not involve buserelin. The mechanistic link is weak because congenital hypertrichosis is not driven by androgen or gonadal signaling.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulator, which are required before any safety screening
- Detailed mechanism of action data (for example from DrugBank)
- Evidence that buserelin or other GnRH agonists have been used in hypertrichosis, or a clearer subtype (such as androgen-driven hirsutism) where the mechanism applies
- Approved indication text for the India licences, to confirm the original indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.